Assessing the comparative safety of novel pulmonary embolism treatments

Roughly 900,000 US patients experience pulmonary embolism annually, and despite newer therapeutic device options, there were no randomized prospective studies comparing them, leaving clinical guidelines out of step with real-world safety in a modern setting. Boston Scientific engaged independent researchers to run a comparative safety analysis using Truveta Data, referenced on the page as the "REAL-PE study," examining major bleeding events associated with novel pulmonary-embolism interventions. The landing page does not disclose the study's specific findings or numbers — it only advertises a downloadable case study covering why traditional data sources are inadequate, methodology, outcome measures, results and research impact.

Truveta is a real-world-data company owned by a consortium of major US health systems, supplying daily-updated de-identified EHR data and a genomic-linkage research program.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.